(EBS) Emergent Biosolutions - Ratings and Ratios

Emergent BioSolutions Inc (NYSE:EBS) is a life sciences company specializing in preparedness and response solutions for public health threats, including accidental, deliberate, and naturally occurring incidents. The company develops and commercializes a portfolio of medical countermeasures and vaccines addressing infectious diseases, chemical and biological threats, and emerging health crises. Its product lineup includes NARCAN Nasal Spray for opioid overdose reversal, Vaxchora for cholera prevention, Vivotif for typhoid fever prevention, Anthrasil for inhalational anthrax treatment, BioThrax as an anthrax vaccine, and CYFENDUS for post-exposure prophylaxis against anthrax. The company also offers Raxibacumab for inhalational anthrax treatment and prophylaxis, ACAM2000 for smallpox vaccination, and TEMBEXA for smallpox treatment. Additional products include BAT for symptomatic botulism, Ebanga for Ebola treatment, and Trobigard, an auto-injector for nerve agent exposure. The company is also advancing a pipeline of experimental treatments, including CGRD-001 for organophosphorus poisoning, EBS-LASV for Lassa fever prevention, and UniFlu for influenza immunity. Emergent BioSolutions provides contract development and manufacturing services, including drug substance production, packaging, and technology transfer. Headquartered in Gaithersburg, Maryland, the company was founded in 1998 and operates as a key player in global public health preparedness.

The companys 3-month forecast indicates potential volatility as the stock trades below its 20-day, 50-day, and 200-day moving averages, suggesting bearish momentum. With an Average True Range (ATR) of 0.63, price fluctuations may remain moderate. Fundamental analysis highlights a forward P/E ratio of 5.93, signaling potential undervaluation, though the negative return on equity (-41.07%) raises concerns about profitability. The price-to-sales ratio of 0.47 reflects modest revenue valuation. Technical resistance may be encountered near the 50-day SMA of 9.46, while support could hold around the 200-day SMA of 8.69. The low price-to-book ratio of 1.04 suggests assets are not overvalued, but the lack of earnings (P/E: 0.00) indicates ongoing operational challenges. The stocks performance will likely hinge on pipeline advancements and execution of its manufacturing services. The upcoming earnings report will be a critical catalyst for price movement.